Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study
Jia Yu, Anwen Xiong, Qiming Wang, Jianhua Chen et autres
Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR-activating mutations. In this phase III, randomized, double-blind trial in China, 336 eligible patients …
cn, ph (code pays fourni par la source)
0 citations
Signal Transduction and Targeted Therapy